Congruence Therapeutics, a Canada-based biotechnology company, announced on Tuesday that it has named Sharath S Hegde, PhD as its new chief scientific officer.
Dr Hegde has served as chief scientific officer at Herophilus and chief scientific officer of Recursion. He has spent more than 15 years at Theravance Biopharma, where he rose from positions of increasing responsibility to assume the role of senior vice president and head of Research. He has served at Syntex Corporation for nine years.
Dr Hegde has PhD in Pharmacology from the University of Houston and B.Pharm/M.Pharm from the University of Mumbai.
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Accent Therapeutics announces executive appointments
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
argenx receives Health Canada approval for VYVGART in gMG
Kyverna Therapeutics signs license and supply agreement with Oxford Biomedica
AffaMed Therapeutics treats first China patient in DEXTENZA Phase three registrational study
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Everest Medicines signs collaboration and license agreement with Kezar Life Sciences
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
Saol Therapeutics completes enrolment in company's two SL-1002 Phase II trials for Osteoarthritis
Purpose Life Sciences adds Jeff Kindler and Calum MacRae to strategic advisory board
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis
Cizzle and Bio-Techne conclude evaluation program for CIZ1B detection